AxoGen, Inc. (NASDAQ:AXGN) is Soleus Capital Management L.P.'s 7th Largest Position

Soleus Capital Management L.P. lowered its stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 1.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,955,943 shares of the medical equipment provider's stock after selling 50,000 shares during the quarter. AxoGen accounts for 3.1% of Soleus Capital Management L.P.'s portfolio, making the stock its 7th largest position. Soleus Capital Management L.P. owned about 6.72% of AxoGen worth $48,714,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Divisadero Street Capital Management LP lifted its holdings in shares of AxoGen by 2.7% during the 4th quarter. Divisadero Street Capital Management LP now owns 26,972 shares of the medical equipment provider's stock valued at $444,000 after buying an additional 700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in AxoGen by 4.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider's stock valued at $398,000 after acquiring an additional 926 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in AxoGen by 8.3% in the fourth quarter. Principal Financial Group Inc. now owns 16,000 shares of the medical equipment provider's stock valued at $264,000 after acquiring an additional 1,228 shares during the period. Rhumbline Advisers boosted its position in AxoGen by 2.7% in the fourth quarter. Rhumbline Advisers now owns 58,232 shares of the medical equipment provider's stock worth $960,000 after purchasing an additional 1,521 shares during the last quarter. Finally, R Squared Ltd purchased a new position in AxoGen in the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 80.29% of the company's stock.

AxoGen Stock Up 0.4%

AXGN stock opened at $11.83 on Monday. The business's 50-day moving average price is $16.13 and its 200-day moving average price is $16.25. The stock has a market cap of $538.79 million, a P/E ratio of -36.97 and a beta of 1.19. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. AxoGen, Inc. has a twelve month low of $5.90 and a twelve month high of $21.00.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AXGN. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $24.00 price target on shares of AxoGen in a research report on Wednesday, March 5th. Lake Street Capital initiated coverage on shares of AxoGen in a report on Monday, March 17th. They set a "buy" rating and a $30.00 target price for the company. Finally, Canaccord Genuity Group dropped their price target on shares of AxoGen from $26.00 to $24.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $22.20.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell sold 5,000 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the sale, the director now directly owns 97,899 shares in the company, valued at $1,959,937.98. This trade represents a 4.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Erick Wayne Devinney sold 15,111 shares of AxoGen stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total transaction of $264,442.50. Following the transaction, the insider now owns 217,762 shares in the company, valued at approximately $3,810,835. This trade represents a 6.49% decrease in their position. The disclosure for this sale can be found here. 2.78% of the stock is owned by company insiders.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.